Summary
Elevance Health, Inc. (ELV) announced on October 4, 2023, an amendment to its Bylaws, effective immediately. This update is primarily driven by the need to align with the Securities and Exchange Commission's (SEC) "universal proxy" rules (Rule 14a-19). The amendments introduce new procedural and informational requirements for shareholders intending to nominate directors at company meetings. Key changes include enhanced disclosure requirements for nominating shareholders regarding their plans and agreements related to the company's securities, a certification mandate to confirm compliance with universal proxy rules regarding proxy statement distribution, and the reservation of a specific proxy card color for the Board's use. These modifications aim to standardize and clarify the director nomination and proxy solicitation processes, ensuring compliance with regulatory updates and potentially strengthening the Board's governance procedures in the context of shareholder activism.
Key Highlights
- 1Elevance Health amended its Bylaws on October 4, 2023.
- 2The amendments are a direct response to the SEC's adoption of "universal proxy" rules (Rule 14a-19).
- 3Shareholders nominating directors must now provide more detailed information about their plans and agreements concerning ELV securities.
- 4A certification is required by nominating shareholders confirming adherence to Rule 14a-19's proxy statement delivery requirements (at least 67% of voting power).
- 5The company has reserved the white color for its proxy cards, with other shareholders required to use different colors.
- 6Shareholder nominations are limited to the number of directors to be elected at a meeting.
- 7The Bylaws clarify that votes for non-compliant nominees may be disregarded.